Bosentan in Digital Ulcers (RAPIDS 2 OL)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Actelion

ClinicalTrials.gov Identifier:

NCT00319696

First received: April 27, 2006

Last updated: September 27, 2012

Last verified: September 2012

History of Changes

Results First Received: June 29, 2012

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Conditions:	Systemic Sclerosis Digital Ulcers
Intervention:	Drug: bosentan

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were enrolled at 33 centers in 7 countries (Canada, France, Germany, Italy, Switzerland, UK, and USA. The first patient enrolled and started treatment on 8 July 2004 and the last patient enrolled and started treatment on 20 October 2005.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients who completed RAPIDS-2 and who still had digital ulcers (DUs) or developed a new digital ulcer (DU) after the last follow-up visit were eligible. After release of the RAPIDS-2 results, patients who were prematurely discontinued from RAPIDS-2 for treatment failure or, if on placebo, for an adverse event and had DUs were also eligible.

Reporting Groups

	Description
Bosentan	Initial dose: bosentan 62.5 mg twice daily (b.i.d.) for the first 4 weeks. Target dose: bosentan 125 mg b.i.d. thereafter

Participant Flow: Overall Study

	Bosentan
STARTED	116
COMPLETED	56
NOT COMPLETED	60
Adverse Event	36
withdrawal of consent	14
administrative	7
Lost to Follow-up	3

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Bosentan	Initial dose: bosentan 62.5 mg twice daily (b.i.d.) for the first 4 weeks. Target dose: bosentan 125 mg b.i.d. thereafter

Baseline Measures

	Bosentan
Number of Participants [units: participants]	116
Age [units: years] Mean ± Standard Deviation	49.3 ± 12.0
Age, Customized [units: participants]
Between 24 and 79 years	116
Gender [units: participants]
Female	87
Male	29
Region of Enrollment [units: participants]
Austria	0
Canada	11
France	10
Germany	9
Italy	9
Switzerland	4
United Kingdom	6
United States	67
Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score ^[1] [units: score on a scale] Mean ± Standard Deviation
Dressing	1.3 ± 0.9
Arising	0.5 ± 0.8
Eating	1.5 ± 1.0
Walking	0.5 ± 0.7
Hygiene	0.9 ± 1.0
Reach	1.1 ± 0.9
Grip	1.1 ± 0.8
Activity	1.0 ± 0.9
Overall hand pain ^[2] [units: mm] Mean ± Standard Deviation	58.62 ± 29.80
United Kingdom Scleroderma Functional Score (UKFS) ^[3] [units: score on a scale] Mean ± Standard Deviation	11.06 ± 7.50

[1]	SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: “without any difficulty”, “with some difficulty,” “with much difficulty,” or “unable to do,” equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
[2]	Overall hand pain related to finger ulcers was assessed by the patient using a Visual Analogue Scale. Patients were instructed to score their pain by marking on the continuous 10-cm scale, where 0 (left) was no pain and 100 (right) very severe pain, in response to the question, “How much pain have you had because of your finger ulcers in the past week?” The investigator measured the distance in millimeters between 0 and the patient mark with the ruler provided and recorded the distance.
[3]	UKFS relates to upper and lower extremity function and muscle weakness. For each item, the patient indicated the responses that best described their current ability: “able to perform in a normal manner,” “able to perform with alteration in style,” “can only manage with difficulty,” and “impossible to achieve.” Each response was given an integer from 0 (able to perform in a normal manner) to 3 (impossible to achieve), and the sum of individual responses provided an overall score of 0 to 33. Missing values were replaced with the worst value the patient reported on the other items at that visit.

Outcome Measures

Show All Outcome Measures

1. Primary:

Total Number of New Digital Ulcers (DUs) Per Patient Observed by the Investigator at Planned Visits [ Time Frame: At planned visits up to week 80 ]

Show Outcome Measure 1

2. Primary:

Time to Complete Healing of Each Baseline DU [ Time Frame: Baseline to healing ]

Show Outcome Measure 2

3. Primary:

Time to Complete Healing of Each New DU [ Time Frame: New DU occurence to healing ]

Show Outcome Measure 3

4. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Dressing [ Time Frame: 80 weeks ]

Show Outcome Measure 4

5. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Arising [ Time Frame: 80 weeks ]

Show Outcome Measure 5

6. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Eating [ Time Frame: 80 weeks ]

Show Outcome Measure 6

7. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Walking [ Time Frame: 80 weeks ]

Show Outcome Measure 7

8. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Hygiene [ Time Frame: 80 weeks ]

Show Outcome Measure 8

9. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Reach [ Time Frame: 80 weeks ]

Show Outcome Measure 9

10. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Grip [ Time Frame: 80 weeks ]

Show Outcome Measure 10

11. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity [ Time Frame: 80 weeks ]

Hide Outcome Measure 11

Measure Type	Primary
Measure Title	Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity
Measure Description	SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time Frame	80 weeks
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
number of participants at baseline, week 16, week 32, week 48, week 64, and week 80 was 116, 99, 93, 85, 82, and 78, respectively

Reporting Groups

	Description
Bosentan	Initial dose: bosentan 62.5 mg twice daily (b.i.d.) for the first 4 weeks. Target dose: bosentan 125 mg b.i.d. thereafter

Measured Values

	Bosentan
Number of Participants Analyzed [units: participants]	116
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity [units: scores on a scale] Mean ± Standard Deviation
change from baseline to week 16	-0.2 ± 0.5
change from baseline to week 32	-0.1 ± 0.7
change from baseline to week 48	-0.1 ± 0.7
change from baseline to week 64	-0.1 ± 0.7
change from baseline to week 80	-0.1 ± 0.6

No statistical analysis provided for Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity

12. Primary:

Mean Changes From Baseline at Each 16 Week Interval up to Week 80 in Overall Hand Pain Related to Finger Ulcers [ Time Frame: 80 weeks ]

Show Outcome Measure 12

13. Primary:

Mean Change From Baseline at Each 16 Week Interval up to Week 80 in the UK Systemic Sclerosis Functional Score (UKFS) [ Time Frame: 80 weeks ]

Show Outcome Measure 13

14. Secondary:

Adverse Events up to 24 Hours After Last Study Medication [ Time Frame: 80 weeks ]

Show Outcome Measure 14

15. Secondary:

Serious Adverse Events up to 28 Days After Last Study Medication [ Time Frame: 80 weeks ]

Show Outcome Measure 15

16. Secondary:

Adverse Events Leading to Permanent Discontinuation of the Study Medication [ Time Frame: 80 weeks ]

Show Outcome Measure 16

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: No text entered.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Andjela Kusic-Pajic, MD/Clinical Project Team Leader
Organization: Actelion Pharmaceuticals Ltd
phone: +41 61 565 64 17

No publications provided

Responsible Party:	Actelion
ClinicalTrials.gov Identifier:	NCT00319696 History of Changes
Other Study ID Numbers:	AC-052-333, RAPIDS-2 OL
Study First Received:	April 27, 2006
Results First Received:	June 29, 2012
Last Updated:	September 27, 2012
Health Authority:	United States: Food and Drug Administration

To Top